News and Press Releases
Latest DB-OTO Results Show Dramatically Improved Hearing to Normal Levels in a Child with Profound Genetic Deafness Within 24 Weeks and Initial Hearing Improvements in a Second Child at Six Weeks
Preliminary data detailed in an ASGCT oral presentation include results for one of the youngest children in the world to receive a gene therapy for genetic deafness Ongoing phase 1/2...
Category: Biotechnology, Clinical Trials
Posted: May 8, 2024
The Charter Building, Vine Street, Uxbridge, Middlesex, United Kingdom, UB8 1JG
First Commercial Cell and Gene Therapy Product Manufactured at Minaris Regenerative Medicine in Allendale, New Jersey, US
With the recent FDA approval of LYFGENIA, developed by bluebird bio, Minaris Regenerative Medicine North America is now supporting a commercial cell and gene therapy (CGT) product The first commercial...
Category: BioManufacturing, Biotechnology
Posted: May 8, 2024
Gilead and Kite Oncology to Highlight Broad and Diverse Oncology Portfolio at ASCO 2024
Non-Small Cell Lung Cancer (NSCLC) Development Program Data to be Presented, Including the phase 3 EVOKE-01 Study Updated Results from phase 2 EDGE-Gastric Study of Fc-Silent Anti-TIGIT Domvanalimab Plus Anti-PD-1...
Category: Clinical Trials, Drug Discovery
Posted: May 7, 2024
Broken String Biosciences and the Francis Crick Institute collaborate to advance ALS research
Partnership to expand applications of DNA break-mapping technology and advance understanding of genomic instability in development of the neurodegenerative disease amyotrophic lateral sclerosis 07 May 2024 -- Cambridge and London,...
Category: Drug Discovery, Pharmaceutical
Posted: May 7, 2024
Unit AB3-04, Level 3 BioData Innovation Centre Wellcome Genome Campus Hinxton Cambridge, CB10 1DR
Revolutionising Patient Care: ProPharma and PBL Launch Innovative Cell & Gene Therapy Manufacturing Device
First-of-its-kind Cell Factory Box streamlines production, making advanced treatments accessible and affordable 2 May 2024 -- Raleigh, North Carolina -- ProPharma, the leading global provider of regulatory, clinical and compliance services...
Category: BioManufacturing, Clinical Trials, Drug Discovery
Posted: May 2, 2024
Kite to Present Comparison of Outcomes of Tecartus (brexucabtagene autoleucel) from the Pivotal ZUMA-2 Trial Versus the EBMT Registry of alloSCT Patients in Mantle Cell Lymphoma (MCL) at 50th EBMT 2024
Additional analysis demonstrates cost-effectiveness of axicabtagene ciloleucel versus standard of care as second-line therapy In patients With large B-cell lymphoma In Italy 9 April 2024 -- Stockley Park, UK --...
Category: Biotechnology, Clinical Trials
Posted: April 12, 2024
NuCana Presents Data at the AACR 2024 Annual Meeting Highlighting the Ability of NUC-7738 to Profoundly Alter Tumour Biology in a Paired Biopsy Clinical Study
NUC-7738 reprogrammes cancer cell lipid metabolism to make tumours less aggressive and promote cancer cell death NUC-7738 alters ribosome biogenesis and the regulation of genes critical for cancer growth and...
Category: Biotechnology, Clinical Trials, Pharmaceutical
Posted: April 10, 2024
Nonacus launches test for comprehensive genomic profiling, integrated with bioinformatics and analysis software
2 April 2024 -- Birmingham, UK -- Genetic testing company, Nonacus, has launched GALEAS Tumor, a next generation sequencing (NGS) test that provides comprehensive genomic profiling of tumours, allowing clinicians...
Category: Biotechnology
Posted: April 2, 2024
Unit 5, Quinton Business Park, 11 Ridgeway, Quinton, Birmingham B32 1AF, United Kingdom
Eisbach and Cancer Focus Fund Announce $4.5m Investment to Support First-in-Human Phase 1/2 Trial of EIS-12656 for Refractory Advanced Solid Tumours
Eisbach is enabling the potential of synthetic lethality by developing novel compounds to exploit molecular vulnerabilities uniquely present in many hard-to-treat cancers 21 March 2024 -- Martinsried, Germany and Texas, US...
Category: Biotechnology, Pharmaceutical
Posted: March 21, 2024
ICR scientists seek new drugs to treat childhood cancer as part of global Cancer Grand Challenges team
6 March 2024 -- London, UK -- A global, interdisciplinary team of researchers has been selected to receive a Cancer Grand Challenges award of up to $25m over five years to tackle...
Category: Clinical Trials, Pharmaceutical
Posted: March 6, 2024
Informed Genomics Limited comments on launch of national BRCA gene testing programme to identify cancer risk early
7 February 2024 -- Birmingham, UK -- NHS England have launched a genetic testing programme targeting tens of thousands of people with Jewish ancestry who are more likely to carry...
Category: Biotechnology
Posted: February 7, 2024
Unit 5, Quinton Business Park, 11 Ridgeway, Quinton, Birmingham, B32 1AF
First MYC inhibitor to demonstrate safety and anti-tumour activity in a phase 1 first-in-human clinical trial
Developed in-house by VHIO-born spin-off company Peptomyc, OMO-103 is a mini-protein targeting the MYC oncogene which is found deregulated in most, if not all tumor types. Until recently, MYC has...
Category: Drug Discovery
Posted: February 7, 2024
Cellular Origins, a TTP Company, appoints Peter Crossley as Chief Operating Officer
Product and technology innovator will build team to further develop and deliver Cellular Origins’ products for cell and gene therapy manufacture at scale 25 January 2024 -- Cambridge, UK --...
Category: BioManufacturing
Posted: January 25, 2024
Calypso Enters into Agreement to Be Acquired by Novartis
Calypso is a European biotech translating Interleukin-15 biology into medical breakthroughs by developing CALY-002, an anti-IL-15 monoclonal antibody, for an array of autoimmune indications The acquisition of Calypso gives Novartis...
Category: Biotechnology
Posted: January 8, 2024
Landmark Phase 3 MARIPOSA Study Shows RYBREVANT▼(amivantamab) Plus Lazertinib Resulted in 30% Reduction in Risk of Disease Progression or Death Compared to Osimertinib in Patients with EGFR-Mutated NSCLC
Early data show an overall survival trend favoring the combination of amivantamab and lazertinib compared to osimertinib; consistent results seen in patients with and without brain metastases Late-breaking results from...
Category: Clinical Trials
Posted: October 24, 2023
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG
